TrialNet	Anti-CD20 Study NEUROLOGIC ASSESSMENT	FORM FORM F
Site Number:	Screening ID:	Participant Letters:
• the first visit for enroll	ogic assessments performed at: ed participants following local IRB ine Visit prior to randomization nths 6, 12, 18, and 24	approval to resume enrollment
VISIT INFORMATION		
1. Was a neurologic assessment	completed at this visit?	Y N
If YES,		/ /
a. Date of assessment:		DAY MONTH YEAR
If NO, complete Section A and o	complete a Protocol Deviation Form (I	RIT21)
approval to resume en Baseline neurologic for new participants)	ssessment (performed during first visi nrollment)	t for enrolled participants following local IRB ning or Baseline Visit <u>prior to randomization</u> 6, 12, 18, and 24)
3. Study Visit: (check one)	Image: 15Month 5Image: 16Month 6Image: 17Month 9Image: 18Month 12Image: 1227Image: 1229Month 24	
. ASSESSMENT INFORMA	τιον	
· ADDEDDIVIENT INFUNITA		

If YES,

• If baseline assessment and clinically significant abnormalities noted, participant is <u>NOT ELIGIBLE</u> for study participation.

• If initial or follow-up assessment and clinically significant abnormalities noted, complete Adverse Event Report Form (**RIT13**) and refer to Neurologist for further evaluation.

Initials (first, middle, last) of person completing this form:		F M L
Date form completed:	DAY MONTH	_/

On all questions write "?" if the desired information is currently unavailable, but is being checked and will be known in future updates. Write "*" if the desired information is permanently unavailable (i.e. will not be known in any future updates).